Annual report pursuant to Section 13 and 15(d)

Subsequent Events Through March 29, 2022

v3.22.1
Subsequent Events Through March 29, 2022
12 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]  
Subsequent Events Through March 29, 2022

13. Subsequent Events

 

On January 6, 2022, the Company entered into a Master Services Agreement with Quotient Sciences Limited, a UK based company that provides drug development and analysis services, for the purpose of performing clinical research in support of UNI-494. 

 

On February 9, 2022, the Company entered into a Master Services Agreement with CBCC Global Research Inc., a California based company that provides clinical trial and related service, for the purpose of performing clinical research in support of Renazorb.